Abbott Vascular's Xience Prime EES Evaluated in Long Coronary Lesions
June 11, 2018—Findings from the multicenter Longprime registry evaluating the performance of the Xience Prime everolimus-eluting stent (Abbott Vascular) in patients with long coronary lesions were published by José Francisco Díaz Fernández, MD, et al online in Catheterization and Cardiovascular Interventions.
As summarized Catheterization and Cardiovascular Interventions, the prospective, multicenter registry was composed of consecutive patients (age, 64.8 ± 11.2 years; 77% men; and 33% diabetics) in 29 tertiary hospitals with > 24-mm de novo lesions in vessels of 2.25 to 4 mm. The primary and secondary endpoints were major adverse cardiac events (MACEs), including cardiac death, myocardial infarction, and target lesion revascularization, as well as and stent thrombosis at 1, 12, and 24 months. Patients were on dual antiplatelet therapy for 12 months.
The study included a total of 610 patients with 705 long lesions (1.2 per patient). Lesion length was 34.59 ± 11.17 mm and vessel size 2.93 ± 0.41 mm. Stented length was 39.83 ± 14.08 mm (1.4 stents per lesion). Pre- and postdilatation were performed in 75% and 33% of the cases, respectively. Intravascular ultrasound was performed in 15% of cases.
The investigators reported that the device success rate was 99.1%. MACE and stent thrombosis rates at 1, 12, and 24 months were 0.3%, 2.1%, and 5.4% and 0.2%, 0.7%, and 1.5%, respectively.
In this real‐world population, the Xience Prime EES performed extremely well in long lesions, with a very low rate of both MACE and stent thrombosis, concluded the investigators in Catheterization and Cardiovascular Interventions.